By Gabriel Paijo 
Triple-negative breast cancer (TNBC) remains one of the most formidable challenges in modern oncology, characterized by its aggressive clinical course, high risk of early metastasis, and a distinct lack of targeted therapeutic options. Unlike other forms of breast cancer that express estrogen receptors, progesterone receptors, or human epidermal growth factor receptor 2 (HER2), TNBC lacks all three. This "triple-negative" status renders conventional hormone therapies and HER2-targeted drugs ineffective, leaving patients primarily reliant on systemic chemotherapy. While many patients initially show a positive response to these toxic regimens, the disease frequently develops resistance, leading to recurrences that are significantly more difficult to treat.
A landmark study recently published in the journal Breast Cancer Research offers a promising new strategy to address this clinical impasse. Researchers at the Medical University of South Carolina (MUSC) Hollings Cancer Center have announced the development of an experimental humanized monoclonal antibody designed to neutralize a specific protein that facilitates tumor growth and suppresses the immune system. In preclinical trials, this novel therapy demonstrated the ability to slow primary tumor growth, inhibit the spread of cancer to the lungs, and—most notably—reinvigorate the body’s natural immune defenses against malignant cells.
The Role of SFRP2 in the Tumor Microenvironment
The focus of the research is a protein known as secreted frizzled-related protein 2 (SFRP2). While SFRP proteins are involved in various physiological processes, the study identifies SFRP2 as a critical enabler of the "pro-tumor" environment in TNBC. According to the research team, SFRP2 acts as a multifunctional survival factor for cancer. It promotes angiogenesis—the formation of new blood vessels that "feed" the tumor—prevents programmed cell death (apoptosis) in cancer cells, and induces a state of "immune exhaustion" in the cells meant to destroy the tumor.
The discovery is the culmination of nearly two decades of investigation led by Nancy Klauber-DeMore, M.D., a breast surgical oncologist and co-leader of the Developmental Cancer Therapeutics Research Program at Hollings Cancer Center. Dr. Klauber-DeMore’s lab first identified SFRP2’s role in breast cancer in 2008. Since that initial discovery, her multidisciplinary team—comprising experts from the departments of Surgery, Biochemistry and Molecular Biology, and Pathology and Laboratory Medicine—has worked to decode the complex molecular pathways through which SFRP2 operates.
"Since 2008, we have discovered its mechanism of action in breast cancer growth, metastasis, and immune exhaustion," Dr. Klauber-DeMore stated. The development of a humanized monoclonal antibody marks a transition from basic biological discovery to a potential clinical intervention. Humanized antibodies are specifically engineered to minimize the risk of being rejected by the human immune system while maintaining high precision in targeting their intended protein.
Reprogramming the Immune Microenvironment
One of the most significant findings of the study involves the "reprogramming" of macrophages within the tumor microenvironment. Macrophages are a type of white blood cell that can exist in two primary states: M1 and M2. M1 macrophages are considered "good" or pro-inflammatory cells that actively attack cancer. Conversely, M2 macrophages are "anti-inflammatory" and are often co-opted by tumors to suppress immune responses and facilitate growth.
In TNBC, the tumor environment typically forces macrophages into the M2 state, effectively creating a shield against the immune system. The MUSC researchers discovered, for the first time, that SFRP2 is expressed directly on these tumor-associated macrophages. By applying the SFRP2 antibody, the team observed a dramatic shift in the macrophage population. The treatment stimulated the release of interferon-gamma, a potent immune signaling molecule, which pushed the macrophages from the suppressive M2 state back into the cancer-fighting M1 state.
Lillian Hsu, M.D., an MUSC surgical resident and a key member of the research team, noted the importance of this mechanism. "We discovered that it pushes macrophages toward the ‘good’ M1 state—without the toxic effects you’d see if you gave interferon-gamma directly," Hsu explained. This finding is particularly relevant for TNBC patients, who often suffer from the cumulative toxicities of traditional treatments. Activating the immune system through a targeted antibody provides a pathway toward efficacy without the systemic damage associated with broader immunotherapy or high-dose cytokine treatments.
Addressing T-Cell Exhaustion and Metastasis
Beyond its effects on macrophages, the SFRP2 antibody appears to address the phenomenon of T-cell exhaustion. T-cells are the primary "soldiers" of the adaptive immune system, but in the presence of an aggressive tumor, they often become overworked and lose their ability to function. The study found that after treatment with the antibody, T-cells in the vicinity of the tumor became more active. This suggests that the therapy could potentially be used in combination with existing checkpoint inhibitors—a class of immunotherapy—to enhance their effectiveness in patients who do not currently respond to them.
The impact on metastasis, the primary cause of cancer-related mortality, was equally striking. In advanced TNBC models, mice treated with the antibody showed a significant reduction in lung tumors compared to untreated control groups. Lung metastasis occurs when cancer cells enter the bloodstream and take root in distant organs, a process that SFRP2 appears to facilitate by strengthening the tumor’s vascular connections. By blocking SFRP2, the antibody effectively limits the "escape routes" for cancer cells.
Furthermore, the researchers utilized bio-distribution tracking to observe where the antibody traveled within the body. The data showed that the antibody accumulated almost exclusively in the tumor tissue. It did not build up in healthy organs or normal immune cells, a characteristic that distinguishes it from many current chemotherapies and suggests a lower risk of side effects in future human trials.
Overcoming Resistance to Standard Chemotherapy
A major hurdle in treating TNBC is the development of resistance to doxorubicin, a standard-of-care chemotherapy often referred to as the "red devil" due to its potency and side effects. Over time, many TNBC tumors adapt to doxorubicin, rendering the drug ineffective.
To test the antibody’s resilience, the MUSC team created cancer cell lines that were specifically resistant to doxorubicin. When these resistant cells were exposed to the SFRP2 antibody, they still underwent significant cell death. This indicates that the pathway used by SFRP2 to keep cancer cells alive is distinct from the pathways targeted by conventional chemotherapy, providing a secondary line of defense for patients whose cancers have evolved to survive standard treatments.
"That’s a very encouraging finding," Dr. Klauber-DeMore said, "because it suggests the therapy may be effective even when standard treatments fail."
Chronology of Development and Future Outlook
The journey of the SFRP2 antibody reflects the rigorous and lengthy process of translational medicine.
- 2008: Dr. Klauber-DeMore’s lab identifies SFRP2 as a key protein expressed in breast cancer.
- 2009–2018: Research focuses on the protein’s role in angiogenesis and its presence in various solid tumors.
- 2019–2022: Development and humanization of the monoclonal antibody. Testing expands to include the immune microenvironment.
- 2023–2024: Publication of the Breast Cancer Research study demonstrating efficacy in TNBC and chemotherapy-resistant models.
The antibody has been licensed to Innova Therapeutics, a biotechnology company based in Charleston, South Carolina. Co-founded by Dr. Klauber-DeMore, Innova is currently working to secure the necessary funding and regulatory approvals for a Phase I first-in-human clinical trial.
While the primary focus of this study was TNBC, the SFRP2 antibody has already gained recognition for its potential in other areas of oncology. The U.S. Food and Drug Administration (FDA) has granted the therapy Rare Pediatric Disease and Orphan Disease designations for the treatment of osteosarcoma, a rare and aggressive bone cancer that also shows high levels of SFRP2 expression. These designations provide financial incentives and an accelerated regulatory pathway, underscoring the medical community’s interest in the SFRP2 pathway as a broad-spectrum oncological target.
Clinical Implications and Analysis
The implications of this research extend beyond a single drug. By identifying SFRP2 as a nexus between tumor growth, immune suppression, and drug resistance, the MUSC team has highlighted a new "vulnerability" in aggressive cancers. If clinical trials prove successful, the SFRP2 antibody could represent a new class of precision medicine that "re-engineers" the tumor environment rather than simply attempting to kill cells with toxicity.
In the broader context of oncology, the shift toward targeting the tumor microenvironment is gaining momentum. The ability to flip the switch on macrophages from a "pro-tumor" to an "anti-tumor" state is a significant step toward making "cold" tumors (those that the immune system ignores) "hot" (those that the immune system attacks).
For patients with Triple-Negative Breast Cancer, who have long faced limited options and high recurrence rates, the development of a targeted therapy that avoids healthy tissue while reviving the immune system offers a significant beacon of hope. While years of clinical testing remain, the preclinical data suggests that SFRP2 may be the key to unlocking new treatments for some of the most difficult-to-treat malignancies in modern medicine.